Lead Product(s): Rabies Immune Globulin [Human]
Therapeutic Area: Infections and Infectious Diseases Product Name: Kedrab
Highest Development Status: Phase IV Product Type: Vaccine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.